Sulpiride

Spezifikationen

15676-16-1CAS-Nummer

239-753-7EG-Nummer

N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamideIUPAC-Name

C15H23N3O4SChemische Formel

341.4 g/molMolekulargewicht

sulpiride; 15676-16-1; Sulpyrid; Sulpirid; Aiglonyl; Dogmatil; Dogmatyl; Dolmatil; Abilit; Guastil; Coolspan; Mirbanil; Misulvan; Neogama; Omperan; Splotin; Sursumid; Meresa; Sernevin; Dobren; Sulpitil; Pyrikappl; Sulpirida; Synedil; N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide; Sulpiridum; Sulpor; DTXSID1042574; RD 1403; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; 5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide; N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide; (+-)-sulpiride; n-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoylbenzamide; N05AL01; 7MNE9M8287; Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-; o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-; NSC-757850; RD-1403; N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoyl-benzamide; DTXCID9022574; CHEBI:32168; 5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-; Sulperide; vertigo neogama; vertigo-neogama; Vertigo Meresa; Vertigo-Meresa; N-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoyl-benzamide; RefChem:56075; N-(1-Ethylpyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoylbenzamide; 239-753-7; (+/-)-Sulpiride; Miradol; Eglonyl; (RS)-(+/-)-sulpiride; Pyrkappl; Sulpiridum [INN-Latin]; Sulpirida [INN-Spanish]; dl-sulpiride; MFCD00055061; R.D. 1403; CHEMBL26; Psicocen; rac Sulpiride; Calmoflorine; Championyl; Lisopiride; Stamonevrol; Alimoral; Darleton; Desmenat; Dresent; Eglonil; Equilid; Eusulpid; Fardalan; Fidelan; Isnamide; Kylistro; Mariastel; Norestran; Nufarol; Ozoderpin; Restful; Suprium; Valirem; Zemorcon; Enimon; Normum; Omiryl; Levosulpiridum [INN-Latin]; Levosulpirida [INN-Spanish]; s4655; Sulpiride-R; (+)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoyl-benzamide; N-(1-ETHYL-2-PYRROLIDINYLMETHYL)-2-METHOXY-5-SULFAMIDOBENZAMIDE; ( inverted exclamation markA)-Sulpiride; SMR000038923; CCRIS 4248; SULPIRIDE,(+); Sulpiride [USAN:INN:BAN:JAN]; SR-01000075402; EINECS 239-753-7; BRN 0494008; UNII-7MNE9M8287; Milsulvan;; Dogmatil;; Dogmatyl;; Mirbanil;; Sulpiride CRS; (+/-)-5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; (y)-Sulpiride; Sulpiride, SLP; ()-Sulpiride; (plusmn)-sulpiride; Dogmatyl (TN); Magnetic resonance imaging sulpiride; (?)-Sulpiride; Prestwick_431; CAS-15676-16-1; Sulpiride (Standard); PS30 - Sulpiride; SULPIRIDE [INN]; SULPIRIDE [JAN]; SULPIRIDE [MI]; SULPIRIDE [USAN]; (.+/-.)-Sulpiride; Prestwick0_000056; Prestwick1_000056; Prestwick2_000056; Prestwick3_000056; SULPIRIDE,(-); Biomol-NT_000037; Biomol-NT_000162; R,S-(+/-)-Sulpiride; SULPIRIDE [MART.]; SCHEMBL8421; SULPIRIDE [WHO-DD]; Lopac0_001050; Oprea1_602476; BSPBio_000211; 5-22-08-00105 (Beilstein Handbook Reference); MLS000069434; MLS001306443; DivK1c_000278; SPBio_002132; BPBio1_000233; BPBio1_000463; BPBio1_001255; GTPL5501; orb1226092; orb1309432; orb3025058; Sulpiride (JP18/USAN/INN); SULPIRIDE [EP IMPURITY]; SCHEMBL29359128; SULPIRIDE [EP MONOGRAPH]; BDBM11638; HMS500N20; HY-B1019R; KBio1_000278; NINDS_000278; Sulpiride 1.0 mg/ml in Methanol; HMS1568K13; HMS2095K13; HMS2231K07; HMS3263A22; HMS3266P12; HMS3371P16; HMS3372O01; HMS3393A08; HMS3411D18; HMS3651G12; HMS3675D18; HMS3712K13; HMS3885J14; HMS5080O10; HMS5083A10; HY-B1019; MSK10053; STR09321; ( inverted question mark)-Sulpiride; Tox21_302205; Tox21_501050; EBC-09094; HB1835; s2104; 5-(Aminosufonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; 5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-benzamide; AKOS004912732; CCG-205127; CS-4534; DB00391; FS27973; LP01050; NSC 757850; SDCCGSBI-0051020.P002; IDI1_000278; NCGC00015966-03; NCGC00015966-04; NCGC00015966-05; NCGC00015966-06; NCGC00015966-07; NCGC00015966-08; NCGC00015966-16; NCGC00024852-02; NCGC00024852-03; NCGC00024852-04; NCGC00024852-05; NCGC00255813-01; NCGC00261735-01; AC-12181; SY235220; DB-046215; EU-0001755; EU-0101050; NS00010476; R. D. 1403; D01226; S 8010; EN300-2010446; F822253; L000579; Q422418; SR-01000075402-2; SR-01000075402-3; SR-01000075402-6; BRD-A55272860-001-03-9; BRD-A55272860-001-04-7; BRD-A55272860-001-08-8; BRD-A55272860-001-14-6; BRD-A55272860-001-15-3; Z84655412; Sulpiride, British Pharmacopoeia (BP) Reference Standard; 1-ethyl-2-(2-methoxy-5-sulfamoylbenzamidomethyl)pyrrolidine; Sulpiride, European Pharmacopoeia (EP) Reference Standard; N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoyl-benzamide; (+/-)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide; (S)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; (RS)-(+/-)-5-Aminosulfonyl-N-[(1-ethyl -2-pyrrolidinyl)methyl]-2-methoxybenzamide; ( inverted question mark)-5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamideSynonyme